Biotech VCs topped tech peers; AMAG Pharmaceuticals rebounds from FDA safety setback;

@FierceBiotech: Amgen widens cancer reach in $1B-plus Micromet deal. Story | Follow @FierceBiotech

> Bruce Booth of Atlas Venture and Highland Capital Partners' Bijan Salehizadeh have a new study that might dispel any myths about life sciences venture capitalist underperforming their tech peers. Blog

> AMAG Pharmaceuticals ($AMAG) took a hit after the FDA slapped safety warnings on its lead drug Feraheme, but the company appears to be making a comeback. Article

> Seeking Alpha has a piece that argues why drug developer Zalicus ($ZLCS) could be takeover bait for large companies like Pfizer ($PFE) and Amgen ($AMGN). Item

> Proteros Biostructures says that it has renewed its pact with Rigel Pharmaceuticals to aid Rigel's drug discovery efforts with its structural biology services. Release

Pharma News

@FiercePharma: Novartis' desire for deals to return soon, CEO says. News | Follow @FiercePharma

> PhRMA: U.S. drug discounts could cost 260K jobs. Report

> Gilead first to jump into AIDS patent pool. Article

> Novartis mulls IPO on China's planned int'l board. Item

> EMA broadens safety review on Sanofi's Multaq. Story

Biotech Research News

> 'Super' stem cell keeps liver cancer going. News

> NCI chief says no retreat from fundamental research. Story

> Sunburn pain discovery could lead to better arthritis treatments. Article

> Hutchinson takes lead on followup to 'Berlin Patient' HIV cure. Report

> Metamark finds proteins that predict melanoma spread. News

> New gonorrhea strain resistant to all available antibiotics. Story

Manufacturing News

> EU may add environmental regs to GMPs. Item

> Lilly: Put law enforcement on the online fakes case. Story

> Tamiflu concentration change aids dosing accuracy. Report

> Chinese chemical inconsistency yields drug 'caveat emptor.' Story

> Oncologist: U.S. may need drug czar to stem shortages. Article

> Make generics look like brand drugs for safety. Item

And Finally... Drug developer Intellikine says that it named former Celgene executive Gregory Berk as its chief medical officer. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.